cefsulodin and Chronic-Disease

Topics: Adult; Cefsulodin; Cephalosporins; Chronic Disease; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Otitis Media; Otorhinolaryngologic Diseases; Pseudomonas Infections

Cefmenoxime (2 g) and cefsulodin (1 g) were given twice daily for 5 days by concomitant intravenous drip infusion (mixed infusion) to 135 patients with complicated urinary tract infection (c-UTI) probably caused by Pseudomonas aeruginosa. The clinical efficacy was evaluated according to the criteria proposed by the UTI committee in Japan. Ninety one subjects met the criteria for c-UTI and were evaluable for drug efficacy. P. aeruginosa was detected in 44 cases (including mixed infection with other organisms). The overall efficacy rate was 73% of the 91 cases; 75% of the 44 cases with P. aeruginosa and 70% in the 47 cases without P. aeruginosa infection. As to bacteriological response, the eradication rate was 91% (105/116) for all cases. By organism, the eradication rate for P. aeruginosa, Serratia spp. and Citrobacter spp. were 82 (36/44), 100 (12/12) and 100% (10/10), respectively. The eradication rate for gram-negative rods was 93% (99/107). Twenty-three strains appeared after treatment, and the majority of them (13) were yeast-like organisms. There was only one strain of P. aeruginosa. As for side effects, eruption was found in 2 cases. Cefmenoxime and cefsulodin were administered concomitantly to patients with c-UTI which was suspected to be caused by P. aeruginosa. The high overall efficacy rate of about 70% on the average was obtained regardless of the causative organism and disease state. The eradication rate of as high as about 90% was obtained excluding Enterococcus faecalis. Neither severe side effects nor abnormal laboratory values were found. It appeared, therefore, that this dosage regimen was useful for the treatment of refractory complicated urinary tract infection.

Topics: Anti-Infective Agents, Urinary; Cefmenoxime; Cefotaxime; Cefsulodin; Chronic Disease; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; Pseudomonas Infections; Urinary Tract Infections

With the recent development of new potential antibiotics, it has become easier to treat patients with common bacterial infections. However, we find it difficult to handle severe infections due to opportunistic pathogens, developed in the so-called immunocompromised patients. SM-4300 is a newly developed intravenous human gamma-globulin, which is said to be intact without conventional enzyme-treatment and sulfonization. SM-4300 is also free from large molecules of aggregated gamma-globulin. SM-4300 was administered in combination with antibiotics to 2 patients of severe respiratory infections, having refractory underlying diseases. Case No. 1 was a 65-year-old female with bronchopneumonia, who had been suffering from pulmonary fibrosis, chronic bronchitis, chronic congestive heart failure and tricuspid insufficiency for several years. During her hospitalization because of these diseases, she developed cough with slight sputum and exertional dyspnea accompanied by high body temperature of 38 degrees C on January 1983. Chest X-ray revealed infiltration in the right lung field which was compatible with bronchopneumonia. SM-4300 of 5 g was added intravenously on 5th day after 4 day-cefotiam treatment with no improvement. High body temperature subsided and laboratory data became normal around 3 days after single SM-4300 injection. Case No. 2 was a 68-year-old male patient of chronic bronchitis with chronic pulmonary emphysema and bronchial asthma. Around the end of May 1983, he complained of dyspnea on exertion and had mucopurulent sputum, more than 100 ml daily, from which Pseudomonas aeruginosa was cultured in large number. He was afebrile.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Aged; Bronchitis; Bronchopneumonia; Cefotaxime; Cefotiam; Cefsulodin; Chronic Disease; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Immunization, Passive; Immunoglobulins; Infusions, Parenteral; Pseudomonas aeruginosa

The clinical effect of cefsulodin (CFS) on Pseudomonas aeruginosa infections in otorhinolaryngology was studied in 10 patients. The overall clinical effectiveness was 80% (excellent 2, good 6, poor 2). Eradication rates of P. aeruginosa was 60%. No side effect and positive skin test were found in any cases. Examination of laboratory data before and after the administration revealed no abnormal findings in every cases.

Topics: Adult; Aged; Cefsulodin; Cephalosporins; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle Aged; Otitis Media; Pseudomonas Infections; Surgical Wound Infection

Clinical evaluation of cefsulodin (CFS) in treatment of infection in otorhinolaryngologic field was carried out and the following result was obtained. 1. Daily 1 to 5 gram of CFS was administered in divided dose to 9 cases of chronic purulent middle ear infection and postoperative wound infection. Clinical effectiveness was excellent, good and fair in 1, 2 and 5 cases, respectively. 2. No side effect as well as abnormal change of laboratory finding was observed. As for ototoxicity to be the most concerned matter of physicians, CFS seems to have no special problem. Thus, CFS is considered to be the useful drug for the treatment of chronic purulent middle ear infection and postoperative wound infection caused by P. aeruginosa in the field of otorhinolaryngology, and synergistic clinical effect will be expected by the combination therapy with other antibiotics or local administration of CFS.

Topics: Cefsulodin; Cephalosporins; Chronic Disease; Drug Evaluation; Female; Humans; Male; Otitis Media; Pseudomonas Infections; Surgical Wound Infection